Highlights United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
489.31 ^USD	+1.08%		+0.68%	+38.68%

12-05	United Therapeutics Insider Sold Shares Worth $3,821,130, According to a Recent SEC Filing	MT
12-02	United Therapeutics Insider Sold Shares Worth $10,798,079, According to a Recent SEC Filing	MT

Highlights

United Therapeutics Insider Sold Shares Worth $3,600,830, According to a Recent SEC Filing	11-12	MT
United Therapeutics Insider Sold Shares Worth $3,488,423, According to a Recent SEC Filing	11-06	MT
United Therapeutics Insider Sold Shares Worth $9,157,821, According to a Recent SEC Filing	11-05	MT
United Therapeutics Insider Sold Shares Worth $3,554,592, According to a Recent SEC Filing	11-04	MT
United Therapeutics Corporation Announces First Transplant in Expands Clinical Trial of UKidney in Patients with End-Stage Renal Disease	11-03	CI
United Therapeutics Insider Sold Shares Worth $3,538,949, According to a Recent SEC Filing	10-31	MT
United Therapeutics Insider Sold Shares Worth $4,953,760, According to a Recent SEC Filing	10-30	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on July 30, 2025.	10-29	CI
United Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	10-29	CI
Earnings Flash (UTHR) United Therapeutics Posts Q3 EPS $7.16, vs. FactSet Est of $6.96	10-29	MT
United Therapeutics Q3 Net Income, Revenue Rise	10-29	MT
Earnings Flash (UTHR) United Therapeutics Corporation Reports Q3 Revenue $799.5M, vs. FactSet Est of $812.8M	10-29	MT
United Therapeutics Q3 revenue misses estimates	10-29	RE
United Therapeutics Insider Sold Shares Worth $3,399,650, According to a Recent SEC Filing	10-22	MT
United Therapeutics Insider Sold Shares Worth $3,574,444, According to a Recent SEC Filing	10-10	MT
United Therapeutics Insider Sold Shares Worth $3,610,769, According to a Recent SEC Filing	10-08	MT
United Therapeutics Insider Sold Shares Worth $10,130,439, According to a Recent SEC Filing	10-07	MT
United Therapeutics Insider Sold Shares Worth $3,583,612, According to a Recent SEC Filing	10-06	MT
United Therapeutics Insider Sold Shares Worth $3,393,884, According to a Recent SEC Filing	10-01	MT
United Therapeutics Insider Sold Shares Worth $3,436,630, According to a Recent SEC Filing	09-29	MT
United Therapeutics Insider Sold Shares Worth $440,000, According to a Recent SEC Filing	09-25	MT
United Therapeutics Corporation to Review Data from the Successful Teton-2 Pivotal Study of Nebulized Tyvaso®? in Idiopathic Pulmonary Fibrosis	09-19	CI
A September Shiver on Wall Street	09-02
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis	09-02	RE
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis	09-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

United Therapeutics delivers 18th consecutive quarter of topline growth

June 17, 2025 at 08:39 am